![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
-
Media ReleaseNEJM publication of Novartis Kisqali® data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Media ReleaseSandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
-
Media ReleaseSandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
-
Media ReleaseSandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
-
Media ReleaseNovartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
-
Media ReleaseNovartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
-
Media ReleaseNovartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
-
Media ReleaseNovartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Media ReleaseNew Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Media ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- › Next page